Block Journal
No Result
View All Result
  • Login
en English
nl Nederlandsen Englishfr Françaisde Deutschit Italianopt Portuguêsru Русскийes Españolth ไทยzh-CN 简体中文hi हिन्दीja 日本語
  • Home
  • News
  • Crypto
  • Markets
  • Investing
  • Glossary
  • Videos
  • Charts
    • Crypto
    • Forex
    • Stocks
    • Commodities
  • Magazine
Magazine
Newsletter
  • Trending Now
  • Bitcoin
  • Altcoin
  • Ethereum
  • Analysis
  • Blockchain
  • Metaverse
  • NFT
  • DeFi
  • Web3
  • GameFi
  • ICO
  • Legal
  • Security
Block Journal
  • Home
  • News
  • Crypto
  • Markets
  • Investing
  • Glossary
  • Videos
  • Charts
    • Crypto
    • Forex
    • Stocks
    • Commodities
  • Magazine
en English
nl Nederlandsen Englishfr Françaisde Deutschit Italianopt Portuguêsru Русскийes Españolth ไทยzh-CN 简体中文hi हिन्दीja 日本語
No Result
View All Result
Block Journal
No Result
View All Result
  • News
  • Crypto
  • Markets
  • Investing
  • Videos
  • Charts
Home News

Gambian child deaths fuel alarm over rules in ‘world’s biggest pharmacy’ India

News Room by News Room
March 11, 2023
in News
Reading Time: 4 mins read
0 0
A A
0

When Ebrima Saidy’s three-year-old daughter Adama fell sick in September last year, her doctor prescribed a generic drug called promethazine. Nine days later, she died in a hospital, a victim of what has become one of the world’s worst scandals related to the sale of over-the-counter medicine.

At least 70 Gambian children under the age of seven who took promethazine or similar drugs died of acute kidney injury between June and October last year, according to a joint report by the World Health Organization and the Gambian health ministry.

Their deaths have sparked concerns about quality control in India, the self-styled pharmacy of the world, as well as under-resourced regulatory agencies in low-income nations. “I asked myself a thousand and one questions, how could the government have let this happen,” Saidy, a 31-year-old graphic designer, said through tears.

India, which has 20 per cent of the global market for generic drugs, supplies more than 50 per cent of generic drugs sold in Africa, according to Invest India, the government’s national investment promotion and facilitation agency.

A December report by the Gambian parliament’s select committee on health showed the children who died had all been prescribed at least one of four medicines — Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup — imported into Gambia by Atlantic Pharmacy and manufactured by India’s Maiden Pharmaceuticals. This month, the US Centers for Disease Control and Prevention linked the Gambian deaths to Maiden, saying the syrups “were imported from a single Indian manufacturer”.

Maiden Pharmaceuticals, which has been in business since 1990 and also supplies Asia, Africa, eastern Europe, the Middle East and Russia, did not respond to requests for comment. Atlantic Pharmacy, which since 2019 has imported drugs from Maiden, could not be reached for comment.

The WHO in October issued an alert on the four “substandard” products made by Maiden, saying the medicines contained “unacceptable” levels of toxic chemicals used in antifreeze and lubricants.

These chemicals were also found in medicine made by India’s Marion Biotech and sold in Uzbekistan, according to Uzbekistani officials. At least 18 children have died and four people arrested. Marion Biotech, which is set to lose its license, did not respond to requests for comment.

This is not the first time Maiden has faced problems with its drugs. It was convicted in February by a court in the northern Indian state of Haryana for manufacturing substandard ranitidine, an antacid medication. The sentence is suspended pending appeal. Last month, an Indian court sentenced two executives from Maiden, blacklisted by Vietnam’s drug administration in 2014, to two and a half years in jail for their role in exporting the drugs to Vietnam.

“If the company had such a bad track record, why is it still manufacturing?” said Prashant Reddy, a lawyer and co-author of The Truth Pill, a book on India’s drug regulation framework. “Under Indian law, there is supposed to be an annual inspection to see whether drugmakers are observing GMP [good manufacturing practices]. How did they not catch this?”

In a letter to the WHO after its warning on cough syrups, Dr VG Somani, the drugs controller general of India, said a narrative promoted by the world’s media had “adversely impacted the image of India’s pharmaceutical products across the globe”. He said that the four medicines blamed for the deaths in Gambia had been tested at a government laboratory and no toxins were found in them.

For some, this response fell short. “How can you claim to be the pharmacy of the world and then refuse to take any kind of responsibility when these deaths happen?” said Reddy. “This government treats everything as a public relations issue, not a public health issue.”

At a meeting of Indian drugmakers and regulators in February, India’s health minister Mansukh Mandaviya asked participants to “steadfastly work towards making the Indian drugs regulatory system among the best in the world”.

On the Gambian side, the country’s drug regulator, the Medicine Control Agency, admitted to parliament that the country had no quality control laboratory and relied on certificates of analysis supplied by manufacturers.

The absence of sufficient checks means “we’re reliant on good faith assumptions that [Gambian] importers will buy drugs from reputable companies”, said Salieu Taal, president of the Gambia Bar Association.

“If you’re importing from the western world, you’re protected by existing regulations,” said Taal, adding that drugs shipped to the US have to meet regulatory standards there. US and European regulators, which can inspect pharmaceutical factories in India prior to granting import licences, have in the past suspended Indian companies.

“When it comes to Africa and other countries in the global south, the regime is very lax,” Taal said.

Taal alleges there are also conflicts of interest at Gambia’s Medicine Control Agency, where he says regulators also provide medical import licenses to importers for a fee.

The West African Postgraduate College of Pharmacists, a regional body, said there was a “conflict of interest of staff in regulation and having business relations in the private sector” but said those conflicts had been “addressed” without detailing how. The Medicine Control Agency did not respond to requests for comment.

The lack of regulation and Gambia’s perceived lack of an adequate response have infuriated parents.

Ebrima Sagnia, a 42-year-old banker and part-time taxi driver on the weekends, lost his three-year-old son Lamin to acute kidney injury on September 13 2022.

Sagnia showed the Financial Times a cheque for 14,285 dalasis ($234) received as a gift from the district government. He and other families have rejected the offer. “We’re fighting for justice, not money,” he said.

For Saidy, the loss of his daughter Adama is something he has to live with every day. “She was smart and intelligent and I built a jovial relationship with my kids,” he said. “We shared a very positive relationship and now her twin sister always asks where her twin is.”

Read the full article here

ShareTweetSharePinShareShareSend

Related News

News

UK regulator to launch review of private market valuations

September 27, 2023
Binance still struggling to find banking partner in France: Report
News

Binance still struggling to find banking partner in France: Report

September 27, 2023
Navigating the Crypto Landscape: From Ethereum and Solana to the New Frontier of Bitcoin Spark
News

Navigating the Crypto Landscape: From Ethereum and Solana to the New Frontier of Bitcoin Spark

September 27, 2023
News

European and Asian stocks rise on improved China industrial data

September 27, 2023
Mixin Network offers $20M bug bounty to hackers in $200M hack
News

Mixin Network offers $20M bug bounty to hackers in $200M hack

September 27, 2023
Reversal of SBF’s Bail Requested Over Caroline Ellison Diary Leak
News

Evidence Guidelines for SBF’s Trial Released

September 27, 2023
News

Why Linda Yaccarino took on the wildest job in Silicon Valley

September 27, 2023
Gensler testimony – crypto enforcement actions driven by “wide-ranging noncompliance”
News

Gensler testimony – crypto enforcement actions driven by “wide-ranging noncompliance”

September 27, 2023
Important XRP v. SEC Developments, SHIB Team Renounces BONE Contract, and More: Bits Recap Sep 27
News

Important XRP v. SEC Developments, SHIB Team Renounces BONE Contract, and More: Bits Recap Sep 27

September 27, 2023

Discussion about this post

Latest News

Brands look to China’s tropical duty free island paradise for consumer comeback

Renaissance Macro Research points to potential bearish shift in U.S. stock market

September 27, 2023
Marriott sees 2023 EPS growth of up to 29%

Marriott sees 2023 EPS growth of up to 29%

September 27, 2023
SEC Delays Review of ARK 21 Shares Spot Bitcoin ETF – Here’s the New Date

SEC Delays Review of ARK 21 Shares Spot Bitcoin ETF – Here’s the New Date

September 27, 2023
CoinGecko’s Latest Report On Ethereum Liquid Staking Notes 4.4% APY

CoinGecko’s Latest Report On Ethereum Liquid Staking Notes 4.4% APY

September 27, 2023
Terra Luna Classic Community Votes To Reset Validator Commission; LUNC To Rally?

Terra Luna Classic Community Votes To Reset Validator Commission; LUNC To Rally?

September 27, 2023
ADVERTISEMENT

Popular

  • Fed’s Williams: Expects inflation to decline to around 3.25% this year

    Fed Preview: Forecasts from 15 major banks, a pause, but the end of rate hikes?

    0 shares
    Share 0 Tweet 0
  • Galaxy Digital Eyes European Expansion With New Regional CEO

    0 shares
    Share 0 Tweet 0
  • Former Alameda Engineer Exposes Firm’s Role in Bitcoin’s 87% Plunge in 2021

    0 shares
    Share 0 Tweet 0
  • Rite Aid plans to shut down hundreds of stores in bankruptcy – WSJ

    0 shares
    Share 0 Tweet 0
  • Vitalik Buterin Moves More Ethereum, ETH Price Drops Below $1600

    0 shares
    Share 0 Tweet 0
Block Journal

Block Journal is the world’s leading source in blockchain news and updates. Follow us to stay up-to-date with all you need to know in web3.

LEARN MORE »

Recent Posts

  • Renaissance Macro Research points to potential bearish shift in U.S. stock market
  • Marriott sees 2023 EPS growth of up to 29%
  • SEC Delays Review of ARK 21 Shares Spot Bitcoin ETF – Here’s the New Date

Trending Topics

AI Altcoin Analysis Bitcoin Blockchain Commodities Crypto DeFi Ethereum Forex Futures GameFi ICO Interview Investing Legal Markets Metaverse News NFT Security Stocks Uncategorized Videos Web3

Get Informed

The most important crypto and finance news and events of the day

Be the first to know latest important news & events directly to your inbox.

By signing up, I agree to our TOS and Privacy Policy.

  • About
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact

Copyright © 2023 Block Journal - Created by Sawah Solutions.

No Result
View All Result
  • Home
  • News
  • Crypto
  • Markets
  • Investing
  • Glossary
  • Videos
  • Charts
    • Crypto
    • Forex
    • Stocks
    • Commodities
  • Magazine

Copyright © 2023 Block Journal - Created by Sawah Solutions.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.